Abstract
Summary
Alendronate (ALO) and calcitonin (CT), as commonly used antiosteoporosis drugs in current clinical practice, have been experimentally confirmed to produce the effectiveness of promoting osseointegration at the interface between prosthesis and host bone and enhancing the long-term stability of the prosthesis. Our current study compared these two drugs' effects on the osseointegration of prosthesis and found that both of them could promote bone attachment between prosthesis and host bone; moreover, ALO produced more pronounced effectiveness.
Introduction
A series of findings confirmed that ALO and CT improved bone attachment of implant in animals. However, which one shows stronger effectiveness has not yet been reported by previous researches. Our study compared the effects of the two commonly used antiosteoporosis drugs on the bone–prosthesis osseointegration so as to provide valuable reference for current clinical options of medication.
Methods
Forty female SD rats aged 5 months were randomly set into A, B, C, and D groups. Except for group A, the others were ovariectomized to establish osteoporosis model (lumbar bone mineral density (BMD) decreased by 20% 4 weeks after ovariectomy). All the rats received prosthesis implantation at their tibial plateau. Then, the rats in groups C and D were given ALO (7 mg/kg/w) orally and CT (5 IU/kg/day) subcutaneously for 12 weeks, respectively. Prior to the execution, application of tetracycline hydrochloride for staining in vivo was done. After harvesting and embedding, the tibia with implants were cut into thin slides, then the bone histomorphometry was measured to observe the new bone around prosthesis and to calculate the osseointegration rate of the implants. By comparison, the effect of the two drugs on osseointegration was evaluated.
Results
(1) Both ALO and CT can effectively enhance the volume of bone mass surrounding the hydroxyapatite (HA) prosthesis and also significantly lever up osseointegration rate to 63.7% and 45.7%, respectively (p < 0.05). However, ALO produced more periprosthesis osseointegration rate than CT, with difference of 18% (p < 0.05). (2) The rats' lumber BMD increased in both ALO and CT groups, from 0.081 ± 0.009 and 0.078 ± 0.009 to 0.116 ± 0.008 and 0.109 ± 0.010 g/cm2, respectively. Moreover, the effect of ALO was observed more pronounced than that of CT.
Conclusions
In osteoporotic conditions, both administration of ALO orally and CT subcutaneously can enhance periprosthesis bone mass and the effects on osseointegration between host bone and prosthesis. Compared with CT, the effect of ALO is more pronounced.
Similar content being viewed by others
References
Karsdal MA, Henriksen K, Arnold M et al (2008) Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. BioDrugs 22(3):137–144
Viera-Negrón YE, Ruan WH, Winger JN et al (2008) Effect of ovariectomy and alendronate on implant osseointegration in rat maxillary bone. J Oral Implantol 34(2):76–82
Giro G, Gonçalves D, Sakakura CE et al (2008) Influence of estrogen deficiency and its treatment with alendronate and estrogen on bone density around osseointegrated implants: radiographic study in female rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105(2):162–167
Jensen TB, Bechtold JE, Chen X et al (2007) Systemic alendronate treatment improves fixation of press-fit implants: a canine study using nonloaded implants. J Orthop Res 25(6):772–778
Frenkel SR, Jaffe WL, Valle CD et al (2001) The effect of alendronate (Fosamax) and implant surface on bone integration and remodeling in a canine model. J Biomed Mater Res 58(6):645–650
Nociti FH Jr, Sallum AW, Sallum EA, Duarte PM (2002) Effect of estrogen replacement and calcitonin therapies on bone around titanium implants placed in ovariectomized rats: a histometric study. Int J Oral Maxillofac Implants 17(6):786–792
Duarte PM, César-Neto JB, Sallum AW, Sallum EA, Nociti FH Jr (2003) Effect of estrogen and calcitonin therapies on bone density in a lateral area adjacent to implants placed in the tibiae of ovariectomized rats. J Periodontol 74(11):1618–1624
Januário AL, Sallum EA, de Toledo S, Sallum AW, Nociti JF Jr (2001) Effect of calcitonin on bone formation around titanium implant. A histometric study in rabbits. Braz Dent J 12(3):158–162
Chen B-L, Liao W-M, Li F-B, Fu M, Xu D-L (2001) Effect of light weight-bearing activity on bone mineral density, histomorphometry and biomechanics in ovarietomized rats (chinese). Acd J SUMS 22(3):187–191
Chacon GE, Stine EA, Larsen PE, Beck FM, McGlumphy EA (2006) Effect of alendronate on endosseous implant integration: an in vivo study in rabbits. J Oral Maxillofac Surg 64(7):1005–1009
Duarte PM, de Vasconcelos Gurgel BC, Sallum AW, Filho GR, Sallum EA, Nociti FH Jr (2005) Alendronate therapy may be effective in the prevention of bone loss around titanium implants inserted in estrogen-deficient rats. J Periodontol 76(1):107–114
Nociti FH Jr, Sallum EA, Toledo S, Newman HN, Sallum AW (1999) Effect of calcitonin on bone healing following titanium implant insertion. J Oral Sci 41(2):77–80
Giro G, Sakakura CE, Gonçalves D, Pereira RM, Marcantonio E Jr, Orrico SR (2007) Effect of 17beta-estradiol and alendronate on the removal torque of osseointegrated titanium implants in ovariectomized rats. J Periodontol 78(7):1316–1321
Kalu DN (1991) The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15(3):175–191
Licata AA (1997) Bisphosphonate therapy. Am J Med Sci 313:17–22
Im GI, Qureshi SA, Kenney J et al (2004) Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 25(18):4105–4115
Romanello M, Bivi N, Pines A et al (2006) Bisphosphonates activate nucleotide recep tors signaling and induce the expression of Hsp90 in osteoblast-like cell lines. Bone 39(4):739–753
Mehlhorn AT, Rechl H, Gradinger R et al (2008) Alendronate decreases TRACP 5b activity in osteoarthritic bone. Eur J Med Res 13(1):21–25
Nenonen A, Cheng S, Ivaska KK et al (2005) Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20(10):1804–1812
Apone S, Lee MY, Eyre DR (1997) Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone. Bone 21(2):129–136
Byrjalsen I, Leeming DJ, Qvist P et al (2007) Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int 19(3):339–348
Acknowledgements
This work is supported by Guangdong Provincial Science and Technology Program 2007B312004 (to B.-L. Chen).
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
Dr B.-L. Chen and D.-H. Xie contributed equally to this work.
Rights and permissions
About this article
Cite this article
Chen, BL., Xie, DH., Zheng, ZM. et al. Comparison of the effects of alendronate sodium and calcitonin on bone–prosthesis osseointegration in osteoporotic rats. Osteoporos Int 22, 265–270 (2011). https://doi.org/10.1007/s00198-010-1186-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-010-1186-5